Search Results 471-480 of 17418 for alopecia
... alopecia, nausea, and fatigue); Clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association class 3 or 4 congestive ...
0 toxicity (except alopecia and vitiligo) related to prior therapy; however, sensory neuropathy Grade ≤ 2 is acceptable. Clinically significant ...
... alopecia; Women of childbearing potential or fertile men and their partners must be willing to abstain from sexual intercourse or to use an effective form of ...
(Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor.) ...
... alopecia and other non-clinically significant adverse events (AEs); No active brain metastases or epidural disease; patients with brain metastases previously ...
Persistent toxicities (≥ CTCAE Grade 2), with the exception of alopecia, caused by previous cancer therapy. Resting ECG with QTc > 470msec on 2 or more ...
... alopecia. Taxane Naive Patients Only: No prior exposure to taxane therapy of any duration for angiosarcoma. Taxane Pre-treated Patients Only: Prior taxane ...
Note: Except patients with ≤ Grade 2 neuropathy or any grade of alopecia. Has tumor(s) invading a major vascular structure (e.g., carotid artery) or other ...
This inherited condition leads to colon cancer. Treatment consists of having frequent screenings and having surgery to remove all or part of the colon.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.